CD8A and neoplasm: Additionally, recent studies have highlighted that Tcf1 + CD8 + T cells from tumor-draining lymph nodes (TDLNs) are the primary effector cells of PD-1 inhibitors, showing a high level of tumor cell inhibition [148, 149].